胶质母细胞瘤
人口
生物信息学
生物
计算生物学
神经科学
下调和上调
癌症研究
基因表达谱
基因
生物信息学
癌细胞
损失函数
细胞
基因调控网络
SKBR3型
癌症
生物网络
U87型
信号转导
基因缺失
基因表达
HEK 293细胞
细胞培养
作者
Dirk C. Hoffmann,Ling Hai,Alexander Weiand,Melina Müller,Sandra Horschitz,Mehrosh Ahmed,Jan Rombouts,Melissa Hahn,Julius Beichert,Rainer D. Will,Antje Habel,Disha Biswas,Magnus-Carsten Huppertz,Alexandros Kourtesakis,Leon D. Kaulen,Melanie Kuhse,Hannah Rohdjeß,Sophie Heuer,Matthia Karreman,Kai Johnsson
标识
DOI:10.1093/neuonc/noag278
摘要
BACKGROUND: Glioblastoma is orchestrated by pacemaker cancer cells, a rare population preferentially residing at the hubs of tumor cell networks. These cells autonomously generate periodic Ca2+ oscillations that drive glioblastoma network function, resilience, and disease progression. To date, the Ca2+-activated K+ channel KCa3.1 is the only known driver of pacemaker function, calling for studies to identify additional factors - to better understand a key component of glioblastoma pathobiology, and uncover novel therapeutic targets. METHODS: A molecular Ca2+ integrator technology enabled the transcriptional profiling of highly Ca2+-active glioblastoma cells, a population enriched for pacemaker cells. Putative regulators of pacemaker function were interrogated using genetic, pharmacological, and computational approaches across complementary glioblastoma models. RESULTS: We identified a distinct transcriptional program that captures highly Ca2+ active glioblastoma cells, including pacemaker cells, across preclinical models and human glioblastoma specimens. This program comprised upregulated cholesterol biosynthesis enzymes, TM-network markers (Aquaporin-4 and Cystatin C), and the Ca2+-activated K+ channels KCa1.1 and KCa2.3. Amongst these components, in silico modeling identified KCa2.3 as the only channel compatible with executing pacemaker function. Consistently, KCa2.3 expression was increased in pacemaker cells, and both genetic and pharmacological perturbation of KCa2.3 selectively disrupted pacemaker function, resulting in reduced network-wide Ca2+ activity. Ultimately, pharmacological inhibition of KCa2.3 with edelfosine reduced tumor burden in human brain spheroids. CONCLUSIONS: We present the first experimental approach to characterize molecular factors of glioblastoma pacemaker cells in a broad and unbiased manner, and identify KCa2.3 as a novel pacemaker gene and promising therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI